Drug companies work to improve COVID-19 vaccines to fight variants of the coronavirus and other viruses and make them easier to distribute.
Author: Karen Weintraub, USA TODAY
‘Life-altering:’ As millions cope with smell loss from COVID-19, researchers find new explanations and possible treatments
Smell loss afflicts the majority of COVID-19 patients. A new understanding is emerging about what causes it, and eventually, how it might be treated.
Pfizer-BioNTech seeks full FDA approval for COVID-19 vaccine
Like other vaccines available in the U.S., Pfizer-BioNTech have been providing their vaccine under an emergency use authorization.
Pfizer vaccine for adolescents to get FDA authorization; much-anticipated decision opens door for teens 12-15
The Food and Drug Administration is likely to authorize the Pfizer-BioNTech COVID-19 vaccine for adolescents within the next week, according to the New York Times and CNN.
An experimental gene therapy was little Alissa’s only hope. Now, instead of certain death, she faces an uncertain future.
A scientific vision for decades, gene therapy is finally becoming more common in the U.S., fueling optimism for the treatment of rare diseases.
‘The benefits outweigh the risks’: It’s time to allow J&J’s COVID-19 vaccine again, public health experts say
A government advisory committee will meet Friday to determine whether to lift the hold on the single-dose vaccine hailed as a “game-changer.”
‘Like somebody gave me a happy pill:’ Monoclonal antibodies are helping the Americans most at risk for COVID-19
The therapy can be life-saving, especially in the early stages of an infection, and it’s becoming easier to access across the US.
Pfizer COVID-19 vaccine is 90% effective for at least 6 months and protects against South Africa variant, study shows
Volunteers receiving a second dose of the Pfizer-BioNTech vaccine remained more than 90% protected against symptomatic COVID-19.
Pfizer-BioNTech COVID-19 vaccine proves safe and effective for kids ages 12 to 15, company study shows
Vaccination was 100% effective against symptomatic disease in 12- to 15-year-olds, the company-sponsored study of 2,260 adolescents found.
Should US share its COVID-19 vaccine supply with the world? The White House says it will – but not yet.
International community members say the U.S. and other richer nations should be sharing more its COVID-19 vaccine supply with the rest of the world.